354 filings
Page 3 of 18
8-K
jbyhr2m yua3x
3 Nov 22
DBV Technologies Reports Third Quarter Financial Results and Business Update
5:18pm
8-K
hn82q1m3cw8b9b0
4 Oct 22
DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
7:32am
8-K
ygd mp5pjikebtvtzp5
21 Sep 22
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
7:49pm
8-K
4fk6g bh4v44hlm
7 Sep 22
DBV expects to screen the first patient in Q4 2022 and anticipates topline results for the VITESSE study to read out in Q1 2025
7:09pm
EFFECT
ol7n0ugu
12 Aug 22
Notice of effectiveness
12:15am
EFFECT
deu1vj6
12 Aug 22
Notice of effectiveness
12:15am
424B3
p0vhf0vhhbnf
11 Aug 22
Prospectus supplement
4:34pm
424B3
xthzrzotl vvq4g
11 Aug 22
Prospectus supplement
4:30pm
CORRESP
rkjbisqgyb591pjqpsos
9 Aug 22
Correspondence with SEC
12:00am
CORRESP
rrv7wnny92vqj m98
9 Aug 22
Correspondence with SEC
12:00am
UPLOAD
judzyxmq
5 Aug 22
Letter from SEC
12:00am
UPLOAD
gjhanpg
5 Aug 22
Letter from SEC
12:00am
8-K
o3uxzxd c6x52o
1 Aug 22
DBV Technologies Reports Second Quarter 2022 Financial Results
4:45pm
F-6EF
rp643uj2 rmgqo4
18 Jul 22
Automatic registration for ADRs (foreign)
5:18pm
8-K
6wp9vneibcg 4k
13 Jun 22
DBV Technologies Announces Private Placement Financing of $194 Million
4:34pm
8-K
bpq2c5n
7 Jun 22
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
5:30pm
F-6EF
75b0vy65
25 May 22
Automatic registration for ADRs (foreign)
3:58pm